The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Tiglutik
Riluzole · RILUZOLE 50 mg/10mL · Suspension · Oral · Italfarmaco SPA
NDC 11797-0210-01 · 2 BOTTLE, PLASTIC in 1 CARTON / 300 mL in 1 BOTTLE, PLASTIC · NDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- NDA209080
- TE code
- AB
- Approval date
- Sep 5, 2018
- Patents / exclusivity
- 1 patents, 0 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| patent | 8765150 | Mar 12, 2029 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Riluzole (Suspension)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Italfarmaco SPA | RILUZOLE 50 mg/10mL | Aug 1, 2026 | Aug 29, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Tiglutik — NDC 11797-0210-01," retrieved September 3, 2026, https://drugdashboards.com/drug/11797021001.
Free to cite with attribution — see how the data is put together.